A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

The main inclusion criteria include but are not limited to the following:

• Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)

• The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment

The main exclusion criteria include but are not limited to the following

• Has uncontrolled blood pressure at screening

• History of any prior macular laser photocoagulation in the study eye

• History of uveitis in either eye

• History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study

• Has uncontrolled glaucoma in the study eye

• Active retinal disease other than the condition under investigation in the study eye

• Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye